FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607636687> ?p ?o ?g. }

• W2607636687 endingPage "4685" @default.
• W2607636687 startingPage "4685" @default.
• W2607636687 abstract "Abstract Background: Patients (pts) relapsing with CML after allogeneic hematopoietic stem cell transplantation (alloHSCT) may be treated with tyrosine kinase inhibitors (TKI) and/or donor lymphocyte infusions (DLI). As nowadays the majority of CML patients would have received at least imatinib prior to transplantation, we were interested in analizing a) the type of TKI used after alloHSCT, b) the indication for TKI treatment, c) the outcome of this treatment and d) the temporal relationship with DLI if given. Patients and methods: 435 pts received TKI after first allogeneic HSCT for CML for different reasons. Transplants had been performed in first chronic phase (CP1, n=194), accelerated phase (AP, n= 60) or for more advanced disease (blast crisis (BC)/> CP1, n=177) from HLA identical siblings (n=231) or unrelated donors (n=204) between 2000 and 2013. TKI given prior to transplant was imatinib (n=268), dasatinib (n=162), nilotinib (n=88), bosutinib (n=4) and ponatinib (n=7). Median age at transplant was 44 (18.5-68) years, 274 pts (63%) were male. TKI post alloHSCT were given between 2000 and 2015. 1st TKI given was either imatinib (n=223), dasatinib (n=131), nilotinib (n=67), bosutinib (n=2) or ponatinib (12). The indications for TKI therapy were the same as for transplantation (n=262), for relapse/progression/persistent disease (n=124), for prophylaxis/pre-emptive (n=32), planned (n=5), others (n=8) and missing (n=4). Results: Median follow-up from start of TKI was 55 (1-171) months. The median time interval from transplant to TKI was 6 (0.2-165) months. It was longer for TKI given for relapse/progression with 15 (1-89) months and shorter for TKI given for prophylaxis/pre-emptive with 1.6 (0.2-43) months. It was longer for imatinib with 11 (0.2-121) months vs 3.8 (0.2-165) months for other TKI. Imatinib as 1st TKI was mainly given for relapse/progression/persistent disease (48%) and the other TKI for the same reason as for transplantation (83%). 103/223 (46%) of pts with imatinib, 99/131 (76%) with dasatinib, 55/67 (82%) with nilotinib and 11/14 (79%) with bosutinib/ponatinib post-transplantation had been treated with imatinib prior to transplantation. In total, 196 (45%) patients received DLI after alloHSCT, of which 63/435 (14.5%) had DLI prior to TKI post-alloHSCT, 19/435 (4.4%) had DLI at the same time of TKI and 114/435 (26%) had DLI post-TKI. Best response after TKI was complete molecular remission in 17.7%, cytogenetic remission in 4.4%, hematological remission in 20.2% and no response/progression/relapse in 57.7% of pts. 50% of pts treated with imatinib had a response (molecular/cytogenetic/hematological) vs 34% with nilotinib, 33% with dasatinib and 33% with bosutinib/ponatinib, p=0.014. OS was 60% (55-65%) at 5 years. It was 66% (60-73%) with imatinib vs 51% (42-60%) with other TKI, p=0.0024. 5 years RFS was 47% (42-53%). It was 53% (46-60%) with imatinib vs 40% (32-48%) with other TKI, p=0.0102. 5 years RI was 25% (21-30%). It was 21% (16-27%) with imatinib vs 31% (24-38%) with other TKI, p=0.0454. 5 years NRM was 27% (23-32%). It was 26% (20-31%) with imatinib vs 29% (22-36%) with other TKI, p=0.365. In multivariate analysis for OS, imatinib vs other TKI post-transplant did not show anymore an effect, HR 1.19 (0.85-1.67), p=0.317. Factors influencing OS were time from diagnosis to transplant, HR 1.01 (1.00-1.01), p=0.009, AP vs CP1, HR 1.80 (1.11-2.91), p=0.017 and BC/>CP1 vs CP1, HR 2.3 (1.58-3.33), p<0.0001. In multivariate analysis for RFS as for OS, imatinib vs other TKI did not have an effect, HR 1.11 (0.83-1.48), p=0.496. Other factors having a tendency or influencing RFS were time from diagnosis to transplant, HR 1.00 (1.00-1.01), p=0.054, AP vs CP1, HR 1.52 (1.00-2.31), p=0.050 and BC/>CP1 vs CP1, HR 2.11 (1.55-2.88), p<0.001. Conclusion: These data suggest that TKI after alloHSCT induce a response in about 42% of pts regardless of the type of TKI used and that time from diagnosis to transplantation as well as the phase of disease at transplant remain the main factors influencing the outcome of CML patients relapsing after alloHSCT. Disclosures Kröger: Riemser: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Neovii: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding." @default.
• W2607636687 created "2017-05-05" @default.
• W2607636687 creator A5001646221 @default.
• W2607636687 creator A5009079290 @default.
• W2607636687 creator A5014507337 @default.
• W2607636687 creator A5017565182 @default.
• W2607636687 creator A5030235127 @default.
• W2607636687 creator A5035666187 @default.
• W2607636687 creator A5036384569 @default.
• W2607636687 creator A5041128935 @default.
• W2607636687 creator A5048440121 @default.
• W2607636687 creator A5050987906 @default.
• W2607636687 creator A5054208517 @default.
• W2607636687 creator A5058925624 @default.
• W2607636687 creator A5066560929 @default.
• W2607636687 creator A5068744991 @default.
• W2607636687 creator A5070706427 @default.
• W2607636687 creator A5076328910 @default.
• W2607636687 creator A5076651597 @default.
• W2607636687 creator A5076984999 @default.
• W2607636687 creator A5080330116 @default.
• W2607636687 creator A5083504452 @default.
• W2607636687 creator A5083961884 @default.
• W2607636687 creator A5085953785 @default.
• W2607636687 date "2016-12-02" @default.
• W2607636687 modified "2023-09-29" @default.
• W2607636687 title "Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT" @default.
• W2607636687 doi "https://doi.org/10.1182/blood.v128.22.4685.4685" @default.
• W2607636687 hasPublicationYear "2016" @default.
• W2607636687 type Work @default.
• W2607636687 sameAs 2607636687 @default.
• W2607636687 citedByCount "2" @default.
• W2607636687 countsByYear W26076366872018 @default.
• W2607636687 countsByYear W26076366872021 @default.
• W2607636687 crossrefType "journal-article" @default.
• W2607636687 hasAuthorship W2607636687A5001646221 @default.
• W2607636687 hasAuthorship W2607636687A5009079290 @default.
• W2607636687 hasAuthorship W2607636687A5014507337 @default.
• W2607636687 hasAuthorship W2607636687A5017565182 @default.
• W2607636687 hasAuthorship W2607636687A5030235127 @default.
• W2607636687 hasAuthorship W2607636687A5035666187 @default.
• W2607636687 hasAuthorship W2607636687A5036384569 @default.
• W2607636687 hasAuthorship W2607636687A5041128935 @default.
• W2607636687 hasAuthorship W2607636687A5048440121 @default.
• W2607636687 hasAuthorship W2607636687A5050987906 @default.
• W2607636687 hasAuthorship W2607636687A5054208517 @default.
• W2607636687 hasAuthorship W2607636687A5058925624 @default.
• W2607636687 hasAuthorship W2607636687A5066560929 @default.
• W2607636687 hasAuthorship W2607636687A5068744991 @default.
• W2607636687 hasAuthorship W2607636687A5070706427 @default.
• W2607636687 hasAuthorship W2607636687A5076328910 @default.
• W2607636687 hasAuthorship W2607636687A5076651597 @default.
• W2607636687 hasAuthorship W2607636687A5076984999 @default.
• W2607636687 hasAuthorship W2607636687A5080330116 @default.
• W2607636687 hasAuthorship W2607636687A5083504452 @default.
• W2607636687 hasAuthorship W2607636687A5083961884 @default.
• W2607636687 hasAuthorship W2607636687A5085953785 @default.
• W2607636687 hasConcept C121608353 @default.
• W2607636687 hasConcept C126322002 @default.
• W2607636687 hasConcept C143998085 @default.
• W2607636687 hasConcept C2777408962 @default.
• W2607636687 hasConcept C2777413986 @default.
• W2607636687 hasConcept C2777583451 @default.
• W2607636687 hasConcept C2778208673 @default.
• W2607636687 hasConcept C2778729363 @default.
• W2607636687 hasConcept C2778820342 @default.
• W2607636687 hasConcept C2779536868 @default.
• W2607636687 hasConcept C2779695342 @default.
• W2607636687 hasConcept C2779972918 @default.
• W2607636687 hasConcept C2780381907 @default.
• W2607636687 hasConcept C2911091166 @default.
• W2607636687 hasConcept C3019892230 @default.
• W2607636687 hasConcept C71924100 @default.
• W2607636687 hasConcept C90924648 @default.
• W2607636687 hasConceptScore W2607636687C121608353 @default.
• W2607636687 hasConceptScore W2607636687C126322002 @default.
• W2607636687 hasConceptScore W2607636687C143998085 @default.
• W2607636687 hasConceptScore W2607636687C2777408962 @default.
• W2607636687 hasConceptScore W2607636687C2777413986 @default.
• W2607636687 hasConceptScore W2607636687C2777583451 @default.
• W2607636687 hasConceptScore W2607636687C2778208673 @default.
• W2607636687 hasConceptScore W2607636687C2778729363 @default.
• W2607636687 hasConceptScore W2607636687C2778820342 @default.
• W2607636687 hasConceptScore W2607636687C2779536868 @default.
• W2607636687 hasConceptScore W2607636687C2779695342 @default.
• W2607636687 hasConceptScore W2607636687C2779972918 @default.
• W2607636687 hasConceptScore W2607636687C2780381907 @default.
• W2607636687 hasConceptScore W2607636687C2911091166 @default.
• W2607636687 hasConceptScore W2607636687C3019892230 @default.
• W2607636687 hasConceptScore W2607636687C71924100 @default.
• W2607636687 hasConceptScore W2607636687C90924648 @default.
• W2607636687 hasIssue "22" @default.
• W2607636687 hasLocation W26076366871 @default.
• W2607636687 hasOpenAccess W2607636687 @default.
• W2607636687 hasPrimaryLocation W26076366871 @default.
• W2607636687 hasRelatedWork W2085342571 @default.
• W2607636687 hasRelatedWork W2292060205 @default.
• W2607636687 hasRelatedWork W2531370518 @default.

• next